PRESS RELEASE: Fragile X Alliance Clinic Seeks Local Patients for Fragile X Syndrome Clinical Trial

The Fragile X Alliance Clinic at North Caulfield is pleased to announce the opportunity for the Victorian community to participate in a clinical trial (RECONNECT study) to evaluate the potential benefits of an investigational drug to improve behavioural symptoms of the rare genetic condition, Fragile X syndrome (FXS). Participation in RECONNECT is available to qualified patients who are interested in a trial evaluating the safety and efficacy of an investigational transdermal cannabidiol gel (applied to the skin) that is being researched internationally. The Fragile X Alliance Clinic at North Caulfield is one of over 20 sites in four countries which will be conducting the trial.

Children diagnosed with FXS may face daily behavioural and emotional challenges, including anxiety, social withdrawal, irritability and inattention. The RECONNECT trial aims to evaluate changes in patient behaviors over time.

The Fragile X Alliance Clinic at North Caulfield is currently looking for qualified candidates from the community who are interested in participating in an 18-week trial to further explore the effects of this investigational drug. The trial seeks to enroll approximately 200 patients to participate in a randomized, double-blind, placebo-controlled trial. Main eligibility criteria for the trial include: age range from 3 to 17 years, genetically tested for the full mutation of FXS, experiencing behaviour related issues and otherwise in generally good health.

The trial site is located at 263 Glen Eira Road, North Caulfield,Vic 3161.

If you or your loved one would like to apply for the study visit: www.fragilexhelp.com.au

Media Contacts:

Name: Brandy HaslamCompany: Fragile X AllianceEmail: Phone: 210-254-7431

About Fragile X Alliance

View Website